Physician profile
Lori E Ganton
NPI 1528657210
$5,638.66
in general payments reported to CMS, 2019-2025
47 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $982 · 2023: $1,217 · 2024: $1,426 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,389.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $900.68 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $542.97 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $461.06 | 2023-2025 | |
| Glaxosmithkline, LLC. | $422.48 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $379.08 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.19 | 2021-2025 | Jardiance, Ofev, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $329.87 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $275.95 | 2022-2025 | |
| Lilly USA, LLC | $175.73 | 2022-2024 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.30 | 2022-2024 | Caplyta |
| Astellas Pharma US INC | $146.46 | 2023-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $140.39 | 2022-2025 | |
| Insmed, INC. | $89.49 | 2022-2023 | Arikayce |
| Lundbeck LLC | $79.12 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $78.71 | 2023-2025 | Varithena Administration Pack |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Ganton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.